TomTom and Renault launch their first electric vehicle’s in-dash navigation system
At the IAA Frankfurt Motorshow TomTom and Renault today, launch their first in-dash navigation system , specifically designed for electric vehicles and standard fitted on the Fluence Z.E.
The Carminat TomTom Z.E. LIVE receives information from the battery on its current state of charge, which is used to determine the available range of the vehicle. This information is then visualised on the navigation screen, showing the journey against the available range and the routes to the charge stations. This will help to effectively plan charging and remove drivers’ “range anxiety”, giving them confidence that their journey can be completed. The system also includes an eco-routing - providing the driver with an option to select the most energy efficient route.
Finding the right charging station information and location (amongst the 5000+ that will be available in Europe at the end of 2011) is critical to drivers. The TomTom Home application will provide users with the latest charging station list each time they connect their SD card to their computer. The Carminat TomTom Z.E. LIVE will inform the users in real-time about the availability of charge stations en route, allowing them to stop and ‘fill-up’ when needed.
“This is the first navigation system TomTom is launching in the area of electric vehicles and it represents a great milestone for us as a company in this exciting new market. The Carminat TomTom Z.E. LIVE for Fluence Z.E., is also the third major development in the already successful Carminat TomTom series and underlines our fruitful relationship with Renault,” says Giles Shrimpton, Managing Director TomTom Automotive.
“We are very happy with the strong partnership we have developed with TomTom over the years and that we are able to give birth today to the next evolution of our product – the new Carminat TomTom Z.E. LIVE. This solution is a key feature of our new Fluence Z.E. The electric vehicle programme is of great importance to us at Renault and the Carminat TomTom Z.E. LIVE plays a significant role in its success”, says Stephen Norman, Global Marketing & Communications Director, Renault.
In addition, the Carminat TomTom Z.E. LIVE comes with LIVE Services including HD Traffic, providing drivers with its unique dynamic routing; giving them the fastest route to their destination based on the latest traffic situation.
Key Features
- Electric vehicle routing functionality, including routing to and via charge stations, and integration with battery management solution
- Eco-routing function
- Visualisation of available range on the map and navigation display
- Automatic updates of charge stations via TomTom Home with search functions for locating of nearest charge station, as well as those around destination or other location
- HD Traffic – unique combination of real-time traffic, based on a network of over 80 million probes in Europe and dynamic routing
- Local Search
- Weather
- Safety camera alerts, to help the customer to drive more safely and responsibly.
- IQ Routes technology so the user always gets the best route to his destination. This technology calculates your routes based on the real average speeds measured on roads. Always providing you with the fastest route, and most accurate travel time, hour-by-hour, day-by-day, saving you time, money and fuel.
- Advanced Lane Guidance shows which lane to take at junctions so you don’t miss your turn. On the most difficult highway intersections, realistic 3D representation of the junction keeps customers relaxed and safe.
- TomTom Map Share allows the user to make corrections to his/her own map and able to benefit from thousands of corrections made by TomTom users every day.
- END -
About TomTom
Founded in 1991, TomTom (AEX:TOM2) is the world’s leading supplier of in-car location and navigation products and services focused on providing all drivers with the world’s best navigation experience. Headquartered in Amsterdam, TomTom has over 3,500 employees and sells its products in over 40 countries.
Our products include portable navigation devices, in-dash infotainment systems, fleet management solutions, maps and real-time services, including the award winning HD Traffic™.
For the world’s most up-to-date route planner, including live traffic information please visit www.tomtom.com/livetraffic /
For further information, please visit www.tomtom.com
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6859530&lang=en
Contact:
For Corporate Communications, please contact:
Kristina
Nilsson
Tel: +31 (0)20 7 575 194
Email: cc@tomtom.com
or
For
Investor Relations:
Richard Piekaar
Tel: +31 (0)20 7 575
194
Email: ir@tomtom.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom